Eccles S - Search Results

1

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.

Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H, Eccles S. Modjtahedi H, et al. Among authors: eccles s. Int J Cancer. 2003 Jun 10;105(2):273-80. doi: 10.1002/ijc.11055. Int J Cancer. 2003. PMID: 12673691

2

c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies.

Bakir MA, Eccles S, Babich JW, Aftab N, Styles J, Dean CJ, Lambrecht RM, Ott RJ. Bakir MA, et al. Among authors: eccles s. J Nucl Med. 1992 Dec;33(12):2154-60. J Nucl Med. 1992. PMID: 1460508 Free article.

3

Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.

Modjtahedi H, Eccles S, Box G, Styles J, Dean C. Modjtahedi H, et al. Among authors: eccles s. Br J Cancer. 1993 Feb;67(2):254-61. doi: 10.1038/bjc.1993.49. Br J Cancer. 1993. PMID: 7679281 Free PMC article.

4

Clinical radioimmunolocalization with a rat monoclonal antibody directed against c-erbB-2.

Allan SM, Dean CJ, Eccles S, Sacks NP. Allan SM, et al. Among authors: eccles s. Cell Biophys. 1994;24-25:93-8. doi: 10.1007/BF02789219. Cell Biophys. 1994. PMID: 7736545

5

Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen.

Allan SM, Dean C, Fernando I, Eccles S, Styles J, McCready VR, Baum M, Sacks N. Allan SM, et al. Among authors: eccles s. Br J Cancer. 1993 Apr;67(4):706-12. doi: 10.1038/bjc.1993.130. Br J Cancer. 1993. PMID: 8097104 Free PMC article.

6

The product of the c-erbB-2 proto-oncogene as a target for diagnosis and therapy in breast cancer.

Dean CJ, Allan S, Eccles S, McFarlane C, Styles J, Valeri M, Sandle J, Bakir A, Sacks N. Dean CJ, et al. Among authors: eccles s. Year Immunol. 1993;7:182-92. Year Immunol. 1993. PMID: 8103950 Clinical Trial. No abstract available.

7

Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.

Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Dean C. Modjtahedi H, et al. Among authors: eccles s. Cancer Res. 1994 Apr 1;54(7):1695-701. Cancer Res. 1994. PMID: 8137284

8

Immunotherapy with antibodies to the EGF receptor.

Dean C, Modjtahedi H, Eccles S, Box G, Styles J. Dean C, et al. Among authors: eccles s. Int J Cancer Suppl. 1994;8:103-7. doi: 10.1002/ijc.2910570722. Int J Cancer Suppl. 1994. PMID: 8194887

9

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.

Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M. Modjtahedi H, et al. Among authors: eccles s. Br J Cancer. 1996 Jan;73(2):228-35. doi: 10.1038/bjc.1996.40. Br J Cancer. 1996. PMID: 8546911 Free PMC article. Clinical Trial.

10

Phosphocholine and choline content of rat sarcoma cells grown in the presence and absence of serum.

Smith TA, Eccles S, Box G, Titley JC, Leach MO, McCready VR. Smith TA, et al. Among authors: eccles s. Anticancer Res. 1996 May-Jun;16(3B):1389-92. Anticancer Res. 1996. PMID: 8694506

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

334 results

Search Page

Filters